Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

Cancer Research - United States
doi 10.1158/0008-5472.can-09-0484
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

The Inhibition of Cellular Recovery in Human Tumour Cells by Inhibitors of Topoisomerase

British Journal of Cancer
Cancer ResearchOncology
1990English

Ciprofloxacin-Induced Inhibition of Topoisomerase II in Human Lymphoblastoid Cells.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1991English

Mechanism of Topoisomerase II Inhibition by Staurosporine and Other Protein Kinase Inhibitors

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1996English

Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells

PLoS ONE
Multidisciplinary
2009English

The Effect of CRM1 Inhibition on Human Non-Hodgkin Lymphoma Cells

Blood Cancer Journal
OncologyHematology
2019English

Simvastatin-Induced Compartmentalisation of Doxorubicin Sharpens Up Nuclear Topoisomerase II Inhibition in Human Rhabdomyosarcoma Cells

Naunyn-Schmiedeberg's Archives of Pharmacology
MedicinePharmacology
2013English

The Mechanisms of Sensitization of Gastrointestinal Stromal Tumor Cells to DNA Topoisomerase II Inhibitors

Kazan medical journal
2019English

Sensitizing Human Multiple Myeloma Cells to the Proteasome Inhibitor Bortezomib by Novel Curcumin Analogs

International Journal of Molecular Medicine
MedicineGenetics
2011English

Proteasome Inhibitors Block Ikaros Degradation by Lenalidomide in Multiple Myeloma

Haematologica
Hematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy